Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients

Details

Serval ID
serval:BIB_CAAC5F477880
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients
Journal
Transplantation
Author(s)
Minghelli  G., Seydoux  C., Goy  J. J., Burnier  M.
ISSN
0041-1337 (Print)
Publication state
Published
Issued date
07/1998
Volume
66
Number
2
Pages
268-71
Notes
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Jul 27
Abstract
BACKGROUND: The angiotensin II receptor antagonist losartan is an effective antihypertensive agent with unique uricosuric properties. This study evaluates the uricosuric effects of losartan in 10 hypertensive heart transplant patients with hyperuricemia. METHODS: The patients were randomized to receive losartan 50 mg once daily and enalapril 20 mg once daily for 4 weeks according to a double-blind crossover design. Office blood pressure, plasma uric acid levels, and urinary uric acid excretion were monitored throughout the study. RESULTS: Plasma uric acid levels decreased significantly after 4 weeks of treatment with losartan (P<0.05) but not with enalapril. On day 1 and after 1 month of treatment, a significant increase in uric acid excretion was observed only with losartan. Significant decreases in office systolic and diastolic blood pressures were obtained with enalapril but not with losartan. CONCLUSIONS: Losartan effectively lowers plasma uric acid levels in hyperuricemic heart transplant patients.
Keywords
Adult Aged Cross-Over Studies Double-Blind Method Enalapril/pharmacology *Heart Transplantation Humans Losartan/*pharmacology Male Middle Aged Receptors, Angiotensin/*antagonists & inhibitors Uric Acid/blood Uricosuric Agents/*pharmacology
Pubmed
Web of science
Create date
28/01/2008 11:11
Last modification date
20/08/2019 16:45
Usage data